Close Menu


The drug is designed to silence connective tissue growth factor, which is implicated in scarring and fibrosis.

Both drugs are administered subcutaneously using Alnylam's GalNAc conjugates.

The study examined high concentrations of consumed siRNAs and dsRNAs targeting the mouse ortholog of a known pest-control gene.

The therapy is the company's first to feature an optimized version of its GalNAc conjugate delivery technology.

According to its CEO, Silence is aiming to expand into a "full-functioning biotech" with more than just a single product.

Officials said the firm remains confident in its HBV drug despite investors' negative reaction to Phase IIa data.


The company is conducting in vivo testing with the La Jolla Institute for Allergy and Immunology.

The RNAi molecules have been licensed to Solstice Biologics, which is developing them for therapeutic applications.

The trial is set to run in Australia.

RXi Posts Flat Q3 Net Loss


NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week reported its third-quarter financial results, posting a net loss essentially flat with last year as expenses held steady.


Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.

Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.

Slate's Jane Hu compares some at-home genetic tests to astrology.

In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.